Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/II Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Patients With Previously Treated Advanced Solid Tumors

Summary

The purpose of this phase I/II trial is to evaluate the safety and efficacy of anti-PSCA CAR T cells (BPX-601) followed by rimiducid in patients with previously treated, PSCA-positive advanced solid tumors, including pancreatic cancer.

General Information

NCT#: NCT02744287
Study ID: BP-012
Trial Phase: Phase I/II

Trial Sponsor: Bellicum Pharmaceuticals
Therapies Used in This Trial: BPX-601, Rimiducid

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search